JPH03504729A - マルトースに対して親和性のある物質（ＭａｌＥ）と、ＨＩＶウイルスに対する中和特性を有するＣＤ４タンパク質フラグメントとの融合によって生じた融合ＣＤ４ポリペプチド - Google Patents
マルトースに対して親和性のある物質（ＭａｌＥ）と、ＨＩＶウイルスに対する中和特性を有するＣＤ４タンパク質フラグメントとの融合によって生じた融合ＣＤ４ポリペプチドInfo
- Publication number
- JPH03504729A JPH03504729A JP2505325A JP50532590A JPH03504729A JP H03504729 A JPH03504729 A JP H03504729A JP 2505325 A JP2505325 A JP 2505325A JP 50532590 A JP50532590 A JP 50532590A JP H03504729 A JPH03504729 A JP H03504729A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- polypeptide
- hybrid
- male
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 title claims description 63
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 59
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 title claims description 56
- 229920001184 polypeptide Polymers 0.000 title claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 48
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 title claims description 38
- 241000725303 Human immunodeficiency virus Species 0.000 title claims description 13
- 230000003472 neutralizing effect Effects 0.000 title claims description 7
- 239000000126 substance Substances 0.000 title claims description 4
- 230000004927 fusion Effects 0.000 title description 7
- 239000012634 fragment Substances 0.000 title description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 78
- 102000004169 proteins and genes Human genes 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 11
- 229920000856 Amylose Polymers 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 210000001322 periplasm Anatomy 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 210000004897 n-terminal region Anatomy 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 210000000805 cytoplasm Anatomy 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 230000005945 translocation Effects 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims 1
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 125000003071 maltose group Chemical group 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 108010041397 CD4 Antigens Proteins 0.000 description 2
- 101150075764 CD4 gene Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- WVCJSDCHTUTONA-FXQIFTODSA-N Asn-Asp-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WVCJSDCHTUTONA-FXQIFTODSA-N 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101150087426 Gnal gene Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 1
- PBIPLDMFHAICIP-DCAQKATOSA-N Lys-Glu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PBIPLDMFHAICIP-DCAQKATOSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 101100178822 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) htrA1 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010090127 Periplasmic Proteins Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- SXJOPONICMGFCR-DCAQKATOSA-N Pro-Ser-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O SXJOPONICMGFCR-DCAQKATOSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101100277437 Rhizobium meliloti (strain 1021) degP1 gene Proteins 0.000 description 1
- 235000002492 Rungia klossii Nutrition 0.000 description 1
- 244000117054 Rungia klossii Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- GBESYURLQOYWLU-LAEOZQHASA-N Val-Glu-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N GBESYURLQOYWLU-LAEOZQHASA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 101150018266 degP gene Proteins 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- RDYMFSUJUZBWLH-UHFFFAOYSA-N endosulfan Chemical compound C12COS(=O)OCC2C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl RDYMFSUJUZBWLH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000727 fraction Substances 0.000 description 1
- 101150101299 gene 4 gene Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000006392 myotrophin Human genes 0.000 description 1
- 108010058605 myotrophin Proteins 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- -1 propyl β-D-thiogalactoside Chemical compound 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8903557A FR2644463A1 (enExample) | 1989-03-17 | 1989-03-17 | |
| FR89/03557 | 1989-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH03504729A true JPH03504729A (ja) | 1991-10-17 |
Family
ID=9379821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2505325A Pending JPH03504729A (ja) | 1989-03-17 | 1990-03-16 | マルトースに対して親和性のある物質（ＭａｌＥ）と、ＨＩＶウイルスに対する中和特性を有するＣＤ４タンパク質フラグメントとの融合によって生じた融合ＣＤ４ポリペプチド |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0426787A1 (enExample) |
| JP (1) | JPH03504729A (enExample) |
| FR (1) | FR2644463A1 (enExample) |
| WO (1) | WO1990011360A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851828A (en) * | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US7049136B2 (en) | 1991-03-07 | 2006-05-23 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
| US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US5843728A (en) * | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2615528B1 (fr) * | 1987-05-18 | 1991-05-24 | Pasteur Institut | Procede de production d'un polypeptide ayant des proprietes choisies determinees, dans un organisme-hote transforme par un adn recombinant contenant des sequences nucleiques codant pour ce polypeptide et pour une proteine affine d'ose |
-
1989
- 1989-03-17 FR FR8903557A patent/FR2644463A1/fr not_active Withdrawn
-
1990
- 1990-03-16 EP EP19900905557 patent/EP0426787A1/fr not_active Withdrawn
- 1990-03-16 WO PCT/FR1990/000182 patent/WO1990011360A1/fr not_active Ceased
- 1990-03-16 JP JP2505325A patent/JPH03504729A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1990011360A1 (fr) | 1990-10-04 |
| FR2644463A1 (enExample) | 1990-09-21 |
| EP0426787A1 (fr) | 1991-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112048005A (zh) | 新型冠状病毒s蛋白片段多倍体及其制备方法、检测试剂盒、疫苗及药物 | |
| US4822606A (en) | Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences | |
| DE69518838T2 (de) | Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung | |
| JPH07501698A (ja) | 二価特異性ヘテロ二量体 | |
| JPH05507197A (ja) | 結合部位を含む可溶性ペプチド類縁体 | |
| JPS60222429A (ja) | 形質転換宿主細胞中にハイブリッド・ポリペプチドを発現させるｄｎａ発現ベクター | |
| JPH04501051A (ja) | 組換え型ｄｎａ由来ボルデテラ毒素サブユニット類似体 | |
| JP2635035B2 (ja) | Ｃｙｓコドン修飾ＤＮＡ | |
| KR20220116516A (ko) | 변이형 rsv f 단백질 및 그 이용 | |
| KR960005181B1 (ko) | 재조합 htlv-ⅲ 단백질 및 이의 용도 | |
| WO2019109954A1 (zh) | PD-1-Fc融合蛋白及其制备方法和用途 | |
| EP0372352B1 (en) | Aequorin fused with a protein having a specific-binding activity, its preparation, its purification and detection method by its use | |
| JPH03504729A (ja) | マルトースに対して親和性のある物質（ＭａｌＥ）と、ＨＩＶウイルスに対する中和特性を有するＣＤ４タンパク質フラグメントとの融合によって生じた融合ＣＤ４ポリペプチド | |
| JP2718827B2 (ja) | 分泌Ｍａｃ−２結合糖タンパク質 | |
| JP4307838B2 (ja) | Ｇｐ１２０ウイルスタンパク質に対して親和性を示すペプチド、およびその使用 | |
| JPH10509038A (ja) | 免疫、精製及び検出適用のためのたんぱく質、ペプチド及び複合物の高い水準の発現と容易な精製 | |
| US7074411B1 (en) | α-β C4BP-type recombinant heteromultimeric proteins | |
| EP0303625B1 (en) | Polypeptide competitor for immunoglobulin e | |
| JPH03155787A (ja) | Ｅｂｚｄ蛋白質発現系 | |
| Gupta et al. | Recombinant fusion proteins for haemagglutination-based rapid detection of antibodies to HIV in whole blood | |
| JPH04506605A (ja) | トランス活性化作用を有するタンパク質、前記タンパク質を発現させるベクター、セルラインおよびその使用 | |
| JPS61233700A (ja) | 分子クロ−ンされたエイズ関連ポリペプチド | |
| CN114524870A (zh) | 源自于ssx2抗原的短肽 | |
| Radford et al. | Antibodies against an inter‐domain segment of polypeptide chain inhibit active‐site coupling in the pyruvate dehydrogenase multienzyme complex | |
| US6387875B1 (en) | Method of use for murine leukaemia inhibitory factor-binding protein (mLBP) |